問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

National Taiwan University Hospital

Division of Hematology & Oncology

更新時間：2023-09-19

吳宗哲
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

59Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳宗哲

List

71Cases

2025-08-01 - 2030-12-31

Phase I

Active
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

  • Condition/Disease

    Neoplasms

  • Test Drug

    Tablets

Participate Sites
2Sites

Recruiting2Sites

2025-02-01 - 2030-12-31

Phase III

Active
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

  • Condition/Disease

    ALK-positive advanced non–small cell lung cancer (NSCLC)

  • Test Drug

    NVL-655 Alectinib HCl

Participate Sites
4Sites

Recruiting4Sites

2024-08-30 - 2028-03-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2024-11-29 - 2029-03-02

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-03-31 - 2028-01-31

Phase I

Active
A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Metastatic Solid Tumor、 Advanced Solid Tumor

  • Test Drug

    靜脈點滴注射劑 靜脈點滴注射劑

Participate Sites
10Sites

Recruiting10Sites

2024-06-01 - 2030-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2024-04-01 - 2030-01-31

Phase I/II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2024-04-01 - 2030-01-31

Phase I/II

Active
A Phase 1b/2 Open-Label Study of Disitamab Vedotin in Combination With Other Anticancer Therapies in Solid Tumors

  • Condition/Disease

    Breast Neoplasms 、Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Dry powder injection Film-coated tablets

Participate Sites
4Sites

Recruiting4Sites

2025-03-31 - 2028-05-06

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2025-05-01 - 2030-12-01

Phase III

Active
Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC

  • Condition/Disease

    Locally advanced or metastatic RAS-mutant non–small cell lung cancer (NSCLC)

  • Test Drug

    Docetaxel AqVida 20 mg/ml concentrate for solution for infusion

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 6 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB